LONDON (AP) — The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing ...

The European Medicines Agency (EMA) has granted limited approval to Eli Lilly’s (LLY) new Alzheimer’s drug Kisunla, reversing ...

The European Medicines Agency (EMA) cleared the way for the use of another drug to treat Alzheimer's disease on Friday.

Preliminary data from clinical trials of tecovirimat as a treatment for mpox virus infection have given disappointing results ...

Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

European regulators said that Eli Lilly’s Alzheimer’s treatment Kisunla should be approved for select patients.

The European Union's drug regulator has recommended approval of Moderna's updated formulation of COVID-19 shot Spikevax, the ...

The drug is administered subcutaneously twice a year, making it easier for high-risk patients to comply with prophylaxis.

Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug ...

Despite a new setback for Elevidys in Europe, Roche—which markets Sarepta’s gene therapy outside the U.S.—remains committed ...

Eli Lilly and Co. won the backing of European Union regulators for its Alzheimer’s disease drug Kisunla in a specific group ...

The European Union’s health regulatory agency did not endorse approving Elevidys for ambulatory patients with Duchenne ...